Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status

References

• Brewer D D, Catalano R F, Haggerty K, Gainey R R, Fleming C B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998; 93: 73–92
   PubMed Web of Science ®Google Scholar
• Gossop M, Stewart D, Browne N, Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002; 97: 1259–1267
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255–264
   PubMed Web of Science ®Google Scholar
• Sees K L, Delucchi K L, Masson C, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283: 1303–1310
   PubMed Web of Science ®Google Scholar
• Caplehorn J R. A comparison of abstinence-oriented and indefinite methadone maintenance treatment. Int J Addict 1994; 29: 1361–1375
   PubMedGoogle Scholar
• Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Cochrane Review). Cochrane Database Syst Rev 2003, issue 2, CD002207
   Google Scholar
• Mattick R P, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Cochrane Review). Cochrane Database Syst Rev 2003, issue 2, CD002209
   Google Scholar
• Berger H, Schwegler M J. Voluntary detoxification of patients on methadone maintenance. Int J Addict 1973; 8: 1043–1047
   PubMed Web of Science ®Google Scholar
• Cushman P, Dole V P. Detoxification of rehabilitated methadone-maintained patients. JAMA 1973; 226: 747–752
   PubMed Web of Science ®Google Scholar
• Stimmel B, Goldberg J, Cohen M, Rotkopf E. Detoxification from methadone maintenance: risk factors associated with relapse to narcotic use. Ann NY Acad Sci 1978; 311: 173–180
   PubMedGoogle Scholar
• Des J, Joseph H, Dole V P. Long-term outcomes after termination from methadone maintenance treatment. Ann NY Acad Sci 1981; 362: 231–238
   PubMedGoogle Scholar
• Kornør H, Waal H. From opioid maintenance to abstinence: a literature review. Drug Alcohol Rev 2005; 24: 267–274
   PubMed Web of Science ®Google Scholar
• Milby J B. Methadone maintenance to abstinence. How many make it?. J Nerv Ment Dis 1988; 176: 409–422
   PubMed Web of Science ®Google Scholar
• Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62–74
   PubMed Web of Science ®Google Scholar
• Norwegian Board of Health. [Addictive medical agents. Prescription and safety]. Vanedannende legemidler. Forskrivning og forsvarlighet. Norwegian Board of Health, Oslo 2001, IK-2755
   Google Scholar
• Kornør H, Waal H, Ali R L. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug Alcohol Rev 2006; 25: 123–130
   PubMed Web of Science ®Google Scholar
• World Health Organisation. The ICD-10 classification of mental and behavioural disorders, clinical description and diagnostic guidlines. World Health Organisation, Geneva 1992
   Google Scholar
• McLellan A T, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199–1113
   PubMed Web of Science ®Google Scholar
• Kokkevi A, Hartgers C. European Addiction Severity Index (EuropASI). EuropASI Working Group, Zürich 1994, Cost A6
   Google Scholar
• Derogatis L R, Lipman R S, Rickels K, Uhlenhut E H, Covi L. Hopkins Symptom Checklist (Hscl)—Self-Report Symptom Inventory. Behav Sci 1974; 19: 1–15
   PubMedGoogle Scholar
• SPSS Inc. spss for Windows, version 11.0. SPSS Inc., Chicago 2001
   Google Scholar
• Statistics Norway. Age-specific death rates for males and females, 1971 – 2005, Available at: http://www.ssb.no/english/subjects/02/02/10/dode_en/tab-2006-04-27-02-en.html (accessed 29 August 2006)
   Google Scholar
• Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253–263
   PubMed Web of Science ®Google Scholar
• Magura S, Kang S Y. Validity of self-reported drug use in high risk populations: a meta-analytical review. Subst Use Misuse 1996; 31: 1131–1153
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Teesson M, Ali R, et al. Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat 2005; 28: 255–263
   PubMed Web of Science ®Google Scholar
• Kosten T R, Rounsaville B J, Kleber H D. A 2.5-year follow-up of treatment retention and reentry among opioid addicts. J Subst Abuse Treat 1986; 3: 181–189
   PubMedGoogle Scholar
• Melberg H O, Lauritzen G, Ravndal E. Hvilken nytte, for hvem og til hvilken kostnad? En prospektiv studie av stoffmisbrukere i behandling [What benefit, for whom and to what cost? A prospective study of drug abusers in treatment]. Statens institutt for rusmiddelforskning, Oslo 2003, SIRUS rapport 4
   Google Scholar
• Bracy S A, Simpson D D. Status of opioid addicts 5 years after admission to drug abuse treatment. Am J Drug Alcohol Abuse 1982; 9: 115–127
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Treacy S. Change and stability of change after treatment of drug misuse 2-year outcomes from the National Treatment Outcome Research Study (UK). Addict Behav 2002; 27: 155–166
   PubMed Web of Science ®Google Scholar
• Hser Y I, Anglin M D, Fletcher B. Comparative treatment effectiveness. Effects of program modality and client drug dependence history on drug use reduction. J Subst Abuse Treat 1998; 15: 513–523
   PubMed Web of Science ®Google Scholar
• Kosten T R, Morgan C, Kleber H D. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Res Monogr 1992; 121: 101–119
   PubMedGoogle Scholar
• Jasinski D R, Pevnick J S, Griffith J D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35: 501–516
   PubMed Web of Science ®Google Scholar
• Bickel W K, Stitzer M L, Bigelow G E, Liebson I A, Jasinski D R, Johnson R E. A clinical trial of buprenorphine - comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43: 72–78
   PubMed Web of Science ®Google Scholar